Neil H. Segal MD PhD

“Early efficacy and encouraging pharmacodynamic evidence suggest the REGN7075 can enhance immune responses and antitumor immunity to “cold” tumors.”    - Gastrointestinal oncologist Dr. @segaln during his oral session at @ASCO. #ASCO24

Last debate @GreatDebatesCME on Day 1 w/ Dr. 🤩Neil Segal @MSKCancerCenter and Dr. Michael Overman @MDAndersonNews: Is there a role for IO therapy in MSS (pMMR) patients? #immunotherapy #cancer #cancerresearch Yes or no? More GREAT speakers tomorrow on Day 2 👏@YJanjigianMD

Our manuscript was published in Nature Communications! The CEA-CD3 T-cell bispecific antibody, cibisatamab, with or without atezolizumab - including MSS-CRC: phase 1/1b trials. rdcu.be/dHYSb